# Richard H Wilson

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 60 papers | 3,622 citations | 236833 25 h-index | 161767 54 g-index |
| 62 all docs | 62 docs citations | 62 times ranked | 5727 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet, The, 2011, 377, 2103-2114. | 6.3 | 876 |
| 2 | Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 7917-7923. | 3.2 | 361 |
| 3 | Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncology, The, 2011, 12, 642-653. | 5.1 | 232 |
| 4 | Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue. Journal of Clinical Oncology, 2011, 29, 4620-4626. | 0.8 | 178 |
| 5 | Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncology, The, 2014, 15, e447-e460. | 5.1 | 171 |
| 6 | A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemotherapy and Pharmacology, 2013, 71, 1191-1199. | 1.1 | 164 |
| 7 | Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncology, 2017, 3, 1546. | 3.4 | 154 |
| 8 | ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary Clinical Trials, 2016, 51, 56-64. | 0.8 | 129 |
| 9 | Evaluating Many Treatments and Biomarkers in Oncology: A New Design. Journal of Clinical Oncology, 2013, 31, 4562-4568. | 0.8 | 128 |
| 10 | Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. European Journal of Cancer, 2015, 51, 271-281. | 1.3 | 108 |
| 11 | Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 631-639. | 5.1 | 97 |
| 12 | EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. Clinical Cancer Research, 2016, 22, 230-242. | 3.2 | 97 |
| 13 | Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 2018, 67, 179-193. | 6.1 | 73 |
| 14 | A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 2017, 116, 884-892. | 2.9 | 69 |
| 15 | Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors. Journal of Clinical Oncology, 2012, 30, 996-1004. | 0.8 | 68 |
| 16 | Inhibition of WEE1 Is Effective inTP53- andRAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 2021, 39, 3705-3715. | 0.8 | 51 |
| 17 | Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2â€“3 randomised trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 162-171. | 3.7 | 47 |
| 18 | Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 854-862. | 3.7 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Effect of Pulsed Masking on Selected Speech Materials. Journal of the Acoustical Society of America, 1969, 46, 898-906. | 0.5 | 45 |
| 20 | Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy. JCO Precision Oncology, 2018, 2018, 1-15. | 1.5 | 45 |
| 21 | Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget, 2015, 6, 20863-20874. | 0.8 | 41 |
| 22 | Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2016, 12, 141-150. | 1.0 | 40 |
| 23 | BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut, 2017, 66, 2141-2148. | 6.1 | 40 |
| 24 | Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 2017, 117, 203-209. | 2.9 | 38 |
| 25 | ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clinical Cancer Research, 2021, 27, 3641-3648. | 3.2 | 32 |
| 26 | Changing the Paradigmâ€"Multistage Multiarm Randomized Trials and Stratified Cancer Medicine. Oncologist, 2015, 20, 849-851. | 1.9 | 24 |
| 27 | The Effects of the Endocannabinoids Anandamide and 2-Arachidonoylglycerol on Human Osteoblast Proliferation and Differentiation. PLoS ONE, 2015, 10, e0136546. | 1.1 | 23 |
| 28 | Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Modern Pathology, 2017, 30, 1287-1298. | 2.9 | 23 |
| 29 | Dataset for Pathology Reporting of Colorectal Cancer. Annals of Surgery, 2022, 275, e549-e561. | 2.1 | 22 |
| 30 | A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. Clinical Cancer Research, 2017, 23, 1200-1212. | 3.2 | 21 |
| 31 | Effects of the myocardialâ€selective Î±<sub>1</sub>â€adrenoceptor antagonist UKâ€52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs. British Journal of Pharmacology, 1988, 95, 1241-1254. | 2.7 | 20 |
| 32 | Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology, 2021, 39, 3693-3704. | 0.8 | 19 |
| 33 | Doseâ€"Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research, 2014, 20, 5663-5671. | 3.2 | 15 |
| 34 | Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer. Npj Breast Cancer, 2021, 7, 38. | 2.3 | 12 |
| 35 | Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer. Oncologist, 2006, 11, 1018-1024. | 1.9 | 11 |
| 36 | A population-level investigation of cancer clinical trials participation in a UK region. European Journal of Cancer Prevention, 2017, 26, S229-S235. | 0.6 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 2016, 68, 1-10. | 1.3 | 9 |
| 38 | A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 2018, 118, 770-776. | 2.9 | 9 |
| 39 | GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).. Journal of Clinical Oncology, 2016, 34, TPS4154-TPS4154. | 0.8 | 9 |
| 40 | Rare cancers: the greatest inequality in cancer research and oncology treatment. British Journal of Cancer, 2017, 117, 1255-1257. | 2.9 | 8 |
| 41 | Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 2022, 19, 146-157. | 0.7 | 7 |
| 42 | PET-CT as a predictor of outcome in resectable colorectal liver metastases. European Journal of Gastroenterology and Hepatology, 2014, 26, 466-472. | 0.8 | 5 |
| 43 | Delivering a researchâ€enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. Cancer, 2016, 122, 664-673. | 2.0 | 5 |
| 44 | A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic. JCO Clinical Cancer Informatics, 2019, 3, 1-17. | 1.0 | 4 |
| 45 | Nothing to lose: a grounded theory study of patientsâ€™ and healthcare professionalsâ€™ perspectives of being involved in the consent process for oncology trials with non-curative intent. BMC Palliative Care, 2020, 19, 166. | 0.8 | 4 |
| 46 | A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours. British Journal of Cancer, 2022, 127, 92-101. | 2.9 | 4 |
| 47 | Orthogonal MET analysis in a populationâ€representative stage IIâ€“III colon cancer cohort: prognostic and potential therapeutic implications. Molecular Oncology, 2021, 15, 3317-3328. | 2.1 | 3 |
| 48 | Association of a DNA damage response deficiency (DDRD) assay and prognosis in early-stage esophageal adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 4015-4015. | 0.8 | 3 |
| 49 | Association of a specific innate immune response to DNA damage with DNA repair deficient colorectal cancers.. Journal of Clinical Oncology, 2016, 34, 3035-3035. | 0.8 | 3 |
| 50 | Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clinical Colorectal Cancer, 2019, 18, 245-256.e5. | 1.0 | 2 |
| 51 | Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. Trials, 2020, 21, 431. | 0.7 | 2 |
| 52 | Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS1617-TPS1617. | 0.8 | 2 |
| 53 | Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 2021, 28, 100445. | 0.7 | 1 |
| 54 | A systems model of BCL-2 dependent apoptosis to predict stage II CRC patients benefiting from adjuvant chemotherapy and as a prognostic tool for stage III CRC patients with increased risk of recurrence.. Journal of Clinical Oncology, 2016, 34, 3584-3584. | 0.8 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | RE: Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data. Journal of the National Cancer Institute, 2015, 107, djv055-djv055. | 3.0 | 0 |
| 56 | The prognostic and therapeutic value of EpHA2 in early colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, 3581-3581. | 0.8 | 0 |
| 57 | Caspase modelling to predict personalised risk in stage III colorectal cancer (CRC) patients.. Journal of Clinical Oncology, 2016, 34, 11592-11592. | 0.8 | 0 |
| 58 | The EASI-SWITCH trial: Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis.. Journal of Clinical Oncology, 2016, 34, TPS10143-TPS10143. | 0.8 | 0 |
| 59 | TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.. Journal of Clinical Oncology, 2017, 35, 2571-2571. | 0.8 | 0 |
| 60 | Reply to A. Kurreck et al and M.S. Copur et al. Journal of Clinical Oncology, 2022, 40, 1263-1264. | 0.8 | 0 |